Possible Interaction: Methionine and Cabozantinib

“BACKGROUND Cabozantinib is a multikinase inhibitor of MET , VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells.”

“BACKGROUND Cabozantinib inhibits tyrosine kinases including MET , AXL, VEGFR2, RET, KIT, and ROS1 and has demonstrated antitumor activity in multiple tumor types.”

“Micro‐Abstract: Cabozantinib is an inhibitor of receptor tyrosine kinases, including MET , vascular endothelial growth factor receptors, AXL, RET, and ROS1.”

“Abstract Background Cabozantinib is a potent, multitarget inhibitor of MET and vascular endothelial growth factor receptor 2 (VEGFR2).”

“BACKGROUND Cabozantinib is an inhibitor of tyrosine kinases, including MET , vascular endothelial growth factor receptor, AXL and RET.”

“BACKGROUND Cabozantinib is an oral inhibitor of tyrosine kinases including MET , VEGFR, and AXL.”

“ Cabozantinib may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET , VEGFR2, and RET.”

“PURPOSE XL184 cabozantinib ) is a potent inhibitor of MET , vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.”

“ Cabozantinib blocks multiple key pathways of HCC pathogenesis, including VEGFR, MET , and the TAM (TYRO3, AXL, MER) family of receptor kinases, and promotes an immune-permissive tumor microenvironment.”

“ Cabozantinib has potent activity against a variety of kinases, including MET , vascular endothelial growth factor receptor, and AXL, that are associated with sarcoma growth and development.”

“We established a new patient-derived xenograft (PDX) model of pRCC carrying an activating mutation of MET and tested the ability of cabozantinib , an inhibitor of receptor tyrosine kinases including MET , to inhibit tumor growth and metastasis.”